Skip to main content
AI team, focused on depression detection, rejects offer to open-source their innovative technology.

Editorial illustration for Depression‑detecting AI team rejects USD 50,000‑a‑week offer, opts to open‑source

Depression AI Goes Open Source, Bypasses Big Pharma Deal

Depression‑detecting AI team rejects USD 50,000‑a‑week offer, opts to open‑source

Updated: 4 min read

Turning down fifty grand a week is a statement. The founders of Kintsugi, a startup that built an AI to detect depression in a person's voice, just made a huge one.

They were offered a lifeline. A temporary cash infusion to cover payroll, in exchange for a punishing chunk of their company's future. They called it predatory and walked.

Instead of selling a piece of their dream, they set the code free. They open-sourced it.

This is the kind of move that gets called brave and principled. It is. But in the messy world of mental health tech, principle can have sharp edges.

Once a tool designed to screen for depression is publicly available, its creators lose all control. The intended clinic walls vanish. The model can be downloaded, tweaked, and plugged into systems its makers never imagined.

Think hiring algorithms that screen for "emotional instability." Insurance forms that silently analyze your voice for risk. A well-meaning tool, suddenly turned into a mechanism for exclusion.

Rather than accept "predatory" short-term offers to meet payroll -- Chang said one proposal offered around $50,000 a week in exchange for $1 million in equity -- the team decided to open-source most of its technology so others might continue the work. Open-sourcing a mental health screening model also raises concerns about misuse. Tools designed to flag signs of depression or anxiety could, in theory, be deployed outside clinical settings, such as by employers or insurers, without the safeguards typically required in healthcare.

Obviously that shouldn't happen, but once released publicly there is little to prevent the technology from being used in ways its creators did not intend. Nicholas Cummins, a senior lecturer in speech analysis and responsible AI in health at King's College London, told The Verge that open-source releases often lack the detailed "paper trail" regulators expect, including a clear record of how a model was trained, validated, and tested for safety. Without that, he said, bringing a product built on the technology through FDA approval could prove difficult.

Open-sourcing a mental health screening model also raises concerns about misuse.

Cummins points to the practical collapse this choice might cause. Regulators like the FDA need documentation. They need to see the recipe, the test results, the safety checks.

Open-source projects, built on collaboration and iteration, rarely maintain that kind of pristine, audit-ready ledger. So any company that picks up this free code and tries to build a real, approved medical product will hit a wall. The very act of liberation may have doomed its clinical use.

The team avoided one trap, the equity chokehold. They may have stepped into another. They've gifted the world a powerful, sensitive tool with no instructions on how to hold it.

Now we see if the community that receives it will build the ethical casing it desperately needs, or just start using it. The real cost of that fifty thousand dollars won't be known for years.

Common Questions Answered

Why did the Kintsugi team reject a $50,000-a-week investment offer?

The team viewed the investment proposal as 'predatory', involving a $1 million equity stake that they felt would compromise their long-term vision and credibility. Instead of accepting short-term financial relief, they chose to open-source their depression-detecting AI technology to enable continued research and development.

What are the potential risks of open-sourcing a mental health screening AI model?

Open-sourcing a depression detection tool raises significant concerns about potential misuse, particularly by entities like employers or insurers who might inappropriately deploy the technology outside clinical settings. The technology could potentially be used to screen or discriminate against individuals without proper medical context or ethical safeguards.

How long did the Kintsugi team work on their depression-detecting AI before deciding to close the company?

The Kintsugi team dedicated seven years to developing their depression-detection AI technology, navigating complex FDA approval processes and clinical trials. After this extensive period of work, they ultimately chose to release their algorithms as open-source rather than accept what they perceived as unfavorable investment terms.

LIVE03:21OpenAI's Miles Wang in Talks for USD 2B AI Drug Discovery Startup